Genomic profile of advanced breast cancer in circulating tumour DNA
Belinda Kingston(Breast Cancer Now), Nicholas C. Turner(Institute of Cancer Research), Alistair Ring(National Health Service), Richard B. Lanman(C.T. de Wit Graduate School for Production Ecology and Resource Conservation), Isaac García-Murillas(Breast Cancer Now), Michael Hubank(Royal Marsden Hospital), Iain R. Macpherson(Beatson West of Scotland Cancer Centre), Rebecca Roylance(University College London Hospitals NHS Foundation Trust), Rosalind Cutts(Breast Cancer Now), Kimberly C. Banks(Guardant (United States)), Sarah Hrebien(Breast Cancer Now), Hannah Bye(Royal Marsden NHS Foundation Trust), Lucy Kilburn(Institute of Cancer Research), Sarah Kernaghan(Institute of Cancer Research), Laura Moretti(Institute of Cancer Research), Matthew Beaney(Breast Cancer Now), Andrew Wardley(UK Research and Innovation), Claire Swift(Institute of Cancer Research), Jorge S. Reis‐Filho(AstraZeneca (France)), Giselle Walsh-Crestani(Breast Cancer Now), Richard D. Baird(Cancer Research UK), Iris Faull(Guardant (United States)), Katie Wilkinson(Institute of Cancer Research), Judith M. Bliss(Institute of Cancer Research)
Cited by 95
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
|The Lancet|2010|1.6k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k